Fractyl Health (NASDAQ:GUTS) Director Ian Sheffield Buys 35,000 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ian Sheffield bought 35,000 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the acquisition, the director owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Fractyl Health Stock Down 1.1%

Shares of Fractyl Health stock opened at $0.72 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. Fractyl Health, Inc. has a 1 year low of $0.38 and a 1 year high of $2.45. The firm’s 50-day moving average is $0.69 and its two-hundred day moving average is $1.07. The stock has a market cap of $114.85 million, a price-to-earnings ratio of -0.56 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. As a group, research analysts expect that Fractyl Health, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GUTS has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.40.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently modified their holdings of GUTS. Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health in the 3rd quarter valued at approximately $19,298,000. Alyeska Investment Group L.P. purchased a new position in shares of Fractyl Health in the 3rd quarter valued at approximately $8,981,000. Rosalind Advisors Inc. purchased a new position in shares of Fractyl Health in the 3rd quarter valued at approximately $7,950,000. Woodline Partners LP raised its position in shares of Fractyl Health by 821.1% in the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after purchasing an additional 4,908,693 shares during the last quarter. Finally, General Catalyst Group Management LLC purchased a new position in shares of Fractyl Health in the 2nd quarter valued at approximately $7,912,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.